EGFR and cancer: Finally, CAR T1E-engineered NK-92 cells are assessed through co-incubation assays with OSCC and MCF-7 (breast metastatic adenocarcinoma cell lines) to investigate their cytotoxic potential as an effective CAR immunotherapy approach to ErbB+ cancers.